Entity

Colorectal Cancer

Cancer of the colon or rectum — among the most common cancers worldwide and a major focus of screening and drug development.

As of 28 Oct 2026Last evidence 27 Oct 2026

What is happening now

Targeting IGF2BP1 Creates a Mitotic Vulnerability in Colorectal Carcinoma
Reported claim · first reported 26 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers
Complete blood count-derived inflammation indices in colorectal cancer: head-to-head case-control and prognostic analyses with population reference intervals and external replication.
Reported claim · first reported 24 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer - Business Wire
Reported claim · first reported 24 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher
Incyte (INCY) Enters KRAS G12D Colon Cancer Trial Collaboration With New Combo Focus - Simply Wall Street
Reported claim · first reported 24 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher
New biomarker framework proposed for immunotherapy in microsatellite-stable colorectal cancer
Reported claim · first reported 23 Oct 2026 · 1 claim · best-carried claim: 3 separate publishers

All 6 events and claims involving Colorectal Cancer

What changed

Attention Rising: 74 mentions on 28 Oct 2026, against 55 on 7 Oct 2026 (+35%).
State Last recorded change: wire tier went from watch to flagged on 28 Oct 2026 (11 changes recorded since 16 Oct 2026).
Claims No claim first reported since 27 Oct 2026.

How well we know this

1,891 documents · 413 publishers · 7% contain a typed assertion · last evidence 27 Oct 2026

Gap: assertion coverage 0.07: about 93% of mentions carry no typed assertion

In this snapshot’s daily coverage:

Reported alongside Colorectal Cancer

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

Immunotherapy · 330 shared documents
KRAS · 162 shared documents
ctDNA · 137 shared documents · no page of its own yet
Overall Survival · 120 shared documents · no page of its own yet
FDA · 119 shared documents
AI · 113 shared documents
Lung Cancer · 96 shared documents · no page of its own yet
Braf · 92 shared documents · no page of its own yet
MSI-H · 85 shared documents · no page of its own yet
Egfr · 81 shared documents · no page of its own yet

Story momentum

Rising

The word compares 74 mentions on 28 Oct 2026 with 55 on 7 Oct 2026 (+35%); a change of less than 8% either way reads Steady.

Daily mentions -53% from 13 Sept 2026 to 28 Oct 2026, between 35 and 158 a day

How often tracked coverage mentions Colorectal Cancer, day by day.

Market price, cited

Not priced yet

No open prediction market prices a question materially about Colorectal Cancer yet. Ask about Colorectal Cancer

No market price on file: no prediction market prices a question about this name yet

Coverage volume and market price are separate measures.

On the desk: Health & Bio Desk

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/e65e9524bedac8b311cd8e6e returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name colorectal cancer.

{
  "name": "colorectal cancer",
  "label": "Colorectal Cancer",
  "asOf": "2026-10-28",
  "mentions": 74,
  "domains": 13,
  "node": {
    "id": "sb:e/e65e9524bedac8b311cd8e6e",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/e65e9524bedac8b311cd8e6e",
    "knowledgeCutoff": "2026-10-28T16:05:01.506968+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "rising",
  "history": {
    "since": "2026-10-16T13:15:08.667923+00:00",
    "changes": 11
  },
  "whereFrom": {
    "level": "counts",
    "label": "74 mentions across 13 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "13 coverage domains",
        "children": {
          "count": 13,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 68 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving Colorectal Cancer

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

Targeting IGF2BP1 Creates a Mitotic Vulnerability in Colorectal Carcinoma
Reported claim · first reported 26 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers
could not check
Complete blood count-derived inflammation indices in colorectal cancer: head-to-head case-control and prognostic analyses with population reference intervals and external replication.
Reported claim · first reported 24 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers
reported by two
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer - Business Wire
Reported claim · first reported 24 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher
single source
Incyte (INCY) Enters KRAS G12D Colon Cancer Trial Collaboration With New Combo Focus - Simply Wall Street
Reported claim · first reported 24 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher
could not check
New biomarker framework proposed for immunotherapy in microsatellite-stable colorectal cancer
Reported claim · first reported 23 Oct 2026 · 1 claim · best-carried claim: 3 separate publishers
could not check
Retraction Note: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90 α in human colorectal cancer
Reported claim · first reported 22 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers
reported by two

Walk the record from Colorectal Cancer

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.